Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 7/20 | 0.44 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31159736 | 0.91 | GLP1R (0.45) | GLP1RACSS2DRD2TBXA2RLCK | |
| SCHEMBL20266537 | 0.91 | GLP1R (0.45) | GLP1RACSS2DRD2TBXA2RLCK | |
| Hydrochloric Acid SCHEMBL30269640 | 0.90 | GLP1R (0.44) | GLP1RACSS2DRD2TBXA2RLCK | |
| Hydrochloric Acid SCHEMBL28910361 | 0.90 | GLP1R (0.44) | GLP1RACSS2DRD2TBXA2RLCK | |
| SCHEMBL20266456 | 0.88 | GLP1R (0.51) | GLP1RACSS2 | |
| SCHEMBL30740795 | 0.88 | ACSS2 (0.46) | GLP1RACSS2DRD2TBXA2RLCK | |
| SCHEMBL29826815 | 0.88 | ACSS2 (0.46) | GLP1RACSS2DRD2TBXA2RLCK | |
| SCHEMBL24265338 | 0.79 | ACSS2 (0.46) | GLP1RACSS2DRD2TBXA2RLCK | |
| SCHEMBL30740718 | 0.79 | ACSS2 (0.46) | GLP1RACSS2DRD2TBXA2RLCK | |
| SCHEMBL29945891 | 0.78 | DRD2 (0.41) | GLP1RACSS2DRD2TBXA2RLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | PFIZER INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20250340544-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250270196-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2025-08-28 | — | — | US | disclosed |
| US-20250257052-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER INC. (US) | 2025-08-14 | — | — | US | disclosed |
| US-12378230-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-3972596-B1 | COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES | PFIZER (US) | 2025-07-16 | — | — | EP | disclosed |
| US-12331041-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-12319669-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2025-06-03 | — | — | US | disclosed |
| EP-4219487-B9 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER (US) | 2025-03-26 | — | — | EP | disclosed |
| CN-119462621-A | GLP-1 receptor agonists and uses thereof | 辉瑞公司 | 2025-02-18 | — | — | CN | disclosed |
| US-10683281-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-10683281-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-10676465-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-10676465-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-10669259-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2020-06-02 | — | — | US | disclosed |
| EP-3555064-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | Pfizer Inc. (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20190119255-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2019-04-25 | — | — | US | disclosed |
| US-10208019-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2019-02-19 | — | — | US | disclosed |
| WO-2018109607-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| US-20180170908-A1 | GLP-1 Agonists and Uses Thereof | PFIZER INC. (US) | 2018-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669259-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GPR119 | GLP1R 1/4885ACSS2 1602/4885DRD2 3291/4885 |
| US-12331041-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GCGR | GLP1R 1/4885ACSS2 1613/4885DRD2 3464/4885 |
| US-10676465-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GCGR | GLP1R 1/4885ACSS2 1613/4885DRD2 3464/4885 |
| US-20250340544-A1 | GLP-1 Receptor Agonists and Uses Thereof | GLP1R, GIPR, GCGR | GLP1R 1/4885ACSS2 1613/4885DRD2 3464/4885 |
| US-20250257052-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | GLP1R, GIPR, GPR119 | GLP1R 1/4885ACSS2 1602/4885DRD2 3291/4885 |
| US-20180170908-A1 | GLP-1 Agonists and Uses Thereof | GLP1R, GIPR, GPR119 | GLP1R 1/4885ACSS2 1630/4885DRD2 3408/4885 |
| US-10683281-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GCGR | GLP1R 1/4885ACSS2 1613/4885DRD2 3464/4885 |
| US-12319669-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GPR119 | GLP1R 1/4885ACSS2 1602/4885DRD2 3291/4885 |
| US-20190119255-A1 | GLP-1 Receptor Agonists and Uses Thereof | GLP1R, GIPR, GPR119 | GLP1R 1/4885ACSS2 1602/4885DRD2 3291/4885 |
| US-10208019-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GPR119 | GLP1R 1/4885ACSS2 1602/4885DRD2 3291/4885 |
| US-12378230-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GCGR | GLP1R 1/4885ACSS2 1613/4885DRD2 3464/4885 |
| US-20250270196-A1 | GLP-1 Receptor Agonists and Uses Thereof | GLP1R, GIPR, GCGR | GLP1R 1/4885ACSS2 1613/4885DRD2 3464/4885 |
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | GLP1R, GCKR, GPR119 | GLP1R 1/4885ACSS2 354/4885DRD2 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.